FDA Clearance Tracker · P130017-S029
Cologuard Stool DNA-Based Colorectal Cancer Screening Test
Last checked: Nov 20, 2026Latest source record: Sep 20, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Sep 20, 2019
Approved
Time to decision
161 days
Received Apr 12, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P130017-S029
- Device name
- Cologuard Stool DNA-Based Colorectal Cancer Screening Test
- Applicant
- Exact Sciences Corporation
- Applicant location
- Medison, WI
- Received
- Apr 12, 2019
- Decided
- Sep 20, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130017
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to expand the indicated age range for Cologuard Stool DNA-Based Colorectal Cancer Screening Test from 50 years or older to 45 years or older.
Source documents
Other decisions for Exact Sciences Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P230043 · Decided Oct 3, 2024 · 286 days after receipt
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.